Success Metrics

Clinical Success Rate
87.1%

Based on 27 completed trials

Completion Rate
87%(27/31)
Active Trials
1(3%)
Results Posted
52%(14 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_2
5
14%
Ph phase_1
4
11%
Ph phase_3
5
14%
Ph phase_4
17
46%
Ph not_applicable
3
8%

Phase Distribution

4

Early Stage

5

Mid Stage

22

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
4(11.8%)
Phase 2Efficacy & side effects
5(14.7%)
Phase 3Large-scale testing
5(14.7%)
Phase 4Post-market surveillance
17(50.0%)
N/ANon-phased studies
3(8.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.4%

27 of 34 finished

Non-Completion Rate

20.6%

7 ended early

Currently Active

1

trials recruiting

Total Trials

37

all time

Status Distribution
Active(1)
Completed(27)
Terminated(7)
Other(2)

Detailed Status

Completed27
Terminated4
Withdrawn3
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
1
Success Rate
87.1%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (11.8%)
Phase 25 (14.7%)
Phase 35 (14.7%)
Phase 417 (50.0%)
N/A3 (8.8%)

Trials by Status

withdrawn38%
completed2773%
unknown25%
terminated411%
recruiting13%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT04478838Phase 4

"Extended" (Alternate Day) Antipsychotic Dosing

Recruiting
NCT03485417Phase 2

Substance Misuse To Psychosis for Stimulants

Completed
NCT02634463Phase 1

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Completed
NCT03557931Phase 2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT06060886Phase 4

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

Unknown
NCT01584466Not Applicable

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

Withdrawn
NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed
NCT02146547Phase 4

European Long-acting Antipsychotics in Schizophrenia Trial

Completed
NCT03425552Phase 1

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

Completed
NCT01399450Phase 4

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Completed
NCT03730857Phase 1

Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

Completed
NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed
NCT02307396Phase 4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed
NCT00330863Phase 4

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT02918825Not Applicable

Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

Completed
NCT01825928Not Applicable

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

Completed
NCT02462473Phase 2

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Terminated
NCT00766064Phase 4

Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
37